Rory Nealon
Chief Financial Officer and Chief Operating Officer (CFO & COO)

Rory Nealon

Chief Financial Officer and Chief Operating Officer (CFO & COO)

Rory Nealon co-founded Amryt Pharma in August 2015. Prior to that, he was the Chief Financial Officer (from 2003), Chief Operating Officer (from November 2007) and Board Member of Trinity Biotech plc, a diagnostic company listed on Nasdaq. He has also been a Board Member and Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland, as well as an Associate Director at AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group. He holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK.

Dr. Mark Sumeray
Chief Medical Officer (CMO)

Dr. Mark Sumeray

Chief Medical Officer (CMO)

Dr Mark Sumeray joined Amryt Pharma in September 2016. He has almost 20 years’ experience across the pharmaceutical, medical devices and biotech industries, both in the US and UK. Most recently, he spent five years as Chief Medical Officer at Aegerion Pharmaceuticals, a US-based orphan disease biotech company. While there, he had clinical development, medical affairs and pharmacovigilance responsibility for the global approval and launch of a new treatment, Lojuxta^®▼(lomitapide), for the serious and rare genetic disease, Homozygous Familial Hypercholesterolemia. He led the clinical and scientific interactions with global health authorities, including the US Food and Drug Administration. Prior to Aegerion, he was at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He also previously worked at Ethicon, a Johnson & Johnson medical device company, where he was responsible for the clinical group. He spent nine years in clinical practice in the NHS, specialising in cardiovascular surgery and physiology, having qualified as a medical doctor at the University of London.

Dr. Helen Phillips
Head of Medical Affairs

Dr. Helen Phillips

Head of Medical Affairs

Dr Helen Phillips joined Amryt Pharma in December 2016. Prior to joining, she was Medical Director EMEA at Aegerion Pharmaceuticals, where she was responsible for the medical activities supporting Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolaemia (HoFH). Dr. Phillips has over 20 years’ experience in Medical Affairs, working in UK, European and Global roles for AstraZeneca, GSK and Hospira, as well as biotech start-up companies, Aspreva and Vanda. She has a degree in Medicine from Bristol University Medical School and spent six years in the NHS in General Practice.

Kieran Rooney
VP, Strategic Alliances and Licensing

Kieran Rooney

VP, Strategic Alliances and Licensing

Kieran Rooney joined Amryt Pharma as VP, Strategic Alliances and Licensing, in August 2017. Prior to joining Amryt, he was Managing Director of Halo BioConsulting, a global healthcare advisory services firm he founded in 2007, which focused on business alliances and management consulting. Between 2007 and 2017, he worked with over 30 pharmaceutical, biotechnology and professional service companies, including, most recently, Amakem Therapeutics and PwC. Prior to that, Dr. Rooney worked as a consultant to the UK Government and held business development roles at Smith & Nephew, F2G Limited, Pharsight Corporation, and MDS Pharma Services, among others. He has a PhD in Neuropharmacology from the University of Wales, Cardiff.

Derval O’Carroll
Head of Regulatory Affairs

Derval O’Carroll

Head of Regulatory Affairs

Derval has over 25 years’ experience in pharmaceutical industry regulatory affairs. Prior to joining Amryt, Derval was Senior Director of Regulatory Affairs for the NASDAQ‐listed rare diseases company Retrophin Inc., where she provided regulatory, strategic and operational input to product teams managing Retrophin’s development‐stage and commercial products. Before that, Derval worked for 11 years as a Managing Consultant at Real Regulatory Ltd, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance.